TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Pharmaust Limited ( (AU:NUZ) ) has shared an announcement.
Neurizon Therapeutics Limited has issued 42,249,999 fully paid ordinary shares at $0.12 each to institutional and professional investors, as part of a placement announced earlier. This move reflects the company’s compliance with relevant provisions of the Corporations Act and indicates its proactive approach to securing funding for its ongoing projects in neurodegenerative disease treatment, potentially strengthening its market position and stakeholder confidence.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.52 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
More about Pharmaust Limited
Neurizon Therapeutics Limited is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases. The company is advancing its lead drug candidate, NUZ-001, aimed at treating ALS, the most common form of motor neurone disease. Neurizon’s strategy involves accelerating access to effective ALS treatments and exploring broader neurodegenerative applications through international collaborations and rigorous clinical programs.
Average Trading Volume: 319,219
Technical Sentiment Signal: Sell
Current Market Cap: A$73.85M
For a thorough assessment of NUZ stock, go to TipRanks’ Stock Analysis page.